Back
Speaker illustration

undefined undefined undefined

Presentations

Disease progression and outcomes in patients with transthyretin amyloid cardiomyopathy receiving tafamidis

Event: Heart Failure 2025

Topic: Epidemiology, Prognosis, Outcome

Session: Expanding insights from heart failure registries and surveys

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources